Expand Trial Footprints Without Expanding Cryopreservation Risk
For many cell therapy programs, the move from fresh to frozen starting material is treated as the moment when variability starts to come under control. And in many ways, that’s true. Fresh leukapheresis-derived starting material is inherently difficult to build around. It is biologically active, time-sensitive, and highly dependent on how quickly and consistently it can move from collection into the next step of the process. Even under strong operational oversight, additional variables around timing, handling, transport duration, pre-processing wait time, and local execution can all influence the condition of the material before manufacturing ever begins.
That is what makes fresh material such a challenging baseline for programs preparing to expand beyond a small number of sites. The starting point is not entirely fixed. It begins changing as soon as collection is complete, and the program has to keep the rest of the workflow moving tightly enough around it to preserve as much consistency as possible. In early stages, when the footprint is smaller and the number of collections is limited, that may be manageable. But as programs move toward Phase II and Phase III, that model starts to carry more risk. More sites enter the network. More operators touch the process. More regions introduce different timing, infrastructure, documentation expectations, and logistical constraints. At that point, the variability associated with fresh material becomes harder to separate from the variability introduced by everything around it.
Cryopreservation can change that dynamic, but only if the cryopreservation process is controlled with the same level of discipline the program expects from manufacturing. Freezing starting material does not automatically make it standardized. It stabilizes the material only to the extent that the process used to freeze, document, store, and move it is consistent.
Fresh Starting Material Creates a Moving Baseline
Fresh leukapheresis-derived starting material asks the program to organize itself around a narrow window of use. Collection timing, packaging, transport, intake, and manufacturing readiness all have to remain closely aligned, and the material continues to be sensitive to time and handling throughout that sequence.
This creates a difficult operating model for growing programs, where each collection carries slightly different conditions into the workflow. A shipment that takes longer than expected, for example, can change the overall viability of the fresh material.
At small scale, variability can be managed with attention and coordination. But at multi-site or international scale, it’s much harder to know whether the starting material is producing the same input each time. And that matters because manufacturing consistency depends heavily on the consistency of what’s delivered into it.
This is why cryopreserved starting material is quickly becoming so important for cell therapy development. Cryopreservation offers a way to stabilize leukapheresis-derived material at a defined point, reducing the pressures of fresh timing and supporting more deliberate planning between collection and manufacturing. But this only solves the first half of the issue.
Freezing Reduces Variability Only if the Process is Controlled
The decision to move from fresh starting material to frozen only creates control if the cryopreservation process is controlled enough to carry that consistency forward.
Otherwise, the program may solve one problem while creating another. Fresh material variability may be reduced, but cryoprocessing variability can enter in its place. And because the material is now frozen and stored, that variability may be less visible in day-to-day execution even though it remains embedded in the input manufacturing eventually receives.
This is especially important when cryopreservation is managed differently across sites or regions. If one site uses a different workflow or equipment, or has different transfer or biostorage practices, the program may end up with frozen material that appears operationally stable but was not created under equivalent conditions.
Frozen material allows for flexible scheduling, as it can be stored, transported, and introduced into manufacturing when the program is ready for it. But for that flexibility to translate into true operational control, the material has to be produced through a cryopreservation process that is standardized and qualified in a way that supports consistency (and comparability) across the trial footprint.
Cryoport Systems’ IntegriCell® cryopreservation services are built around that principle, using standardized cryopreservation workflows for leukapheresis-derived starting material and integrating those services into the wider end-to-end supply chain that also accounts for biostorage and logistics within a single-vendor (and even single-site) platform.
Site-Specific Cryoprocessing Introduces Risk
Cryopreservation is sometimes talked about as though it’s a single step. But in practice, it’s a controlled workflow made up of many points where variation can enter.
Timing from collection to cryopreservation matters. So does cryoprotectant preparation, automated or controlled-rate freezing parameters, equipment qualification, operator training, labeling, chain of identity and custody capture, transfer into biostorage, biostorage monitoring, and the documentation that connects each of those steps. When any of these elements are handled differently from site to site, the program is no longer working from one standardized frozen input. It can find itself working from multiple locally-produced versions of what is intended to be the same starting material strategy.
That can create downstream operational consequences. Manufacturing teams may see differences in how material enters the run, while quality teams may have to reconcile documentation that doesn’t tell the same story across regions. This is where site-specific cryopreservation can create risk, especially for Phase II and Phase III programs. At this stage, the program needs to be able to demonstrate that the full process performs reliably and consistently as the footprint expands. If cryopreservation practices vary by geography, the program might be introducing inconsistencies at exactly the point where it is trying to create control.
Why Phase II/III Programs Need Cryopreservation That Travels
As programs expand, consistency has to travel with them.
That doesn’t mean that every site or region needs to look identical in every operational detail, but it does mean the critical elements of cryopreservation can’t depend on local interpretation.
This becomes especially important for multi-site and international trials, where local site capability doesn’t always translate into global consistency. A site may be highly capable, sure, but if it’s implementing cryopreservation through its own local process, the program still has to defend how that output compares with material cryopreserved elsewhere.
Unified cryopreservation workflows reduce that risk by giving programs a common operating model. A standardized approach creates value beyond the cryopreservation step itself. It supports predictable manufacturing readiness and cleaner documentation with fewer regional interpretation issues, providing a stronger foundation for global expansion.
Cryoport Systems Supports Consistency Across Regions
With Cryoport Systems, cryopreservation isn’t treated as an isolated service. IntegriCell cryopreservation services are integrated into the end-to-end global temperature-controlled supply chain platform that connects cryopreservation with biostorage, logistics, and broader material management support.
Consistency is difficult to maintain when each part of the workflow is managed separately. A standardized cryopreservation process can lose some of its practical value if the surrounding storage, documentation, transportation, and handoff process are fragmented. Cryoport Systems brings those elements together into a unified framework, supporting manufacture-ready cryopreserved leukopaks and helping programs reduce variability across the full supply chain.
The global network piece is also important. Cryoport Systems has a global footprint of facilities that operate within the same quality framework, with standardized SOPs and globally-aligned protocols. For programs expanding into multi-region trials, that kind of alignment helps to avoid the need to rebuild cryopreservation processes region by region.
Instead, sponsors can work within a more consistent operational framework as they expand. Cryopreservation, biostorage, logistics, documentation, and supporting supply chain activities are connected under standardized expectations and consistent processes, making it easier to support audit readiness while reducing local variation. This allows programs to move forward with confidence into the next milestone.
Building Global Readiness from the Point of Freezing
For cell therapy programs preparing for multi-site or international trials, the move from fresh to frozen starting material can be an important step toward reducing variability. But freezing alone is not the control strategy.
The control strategy is the process around freezing.
If cryopreservation is inconsistent or disconnected from the broader supply chain, the program may still carry variability forward into manufacturing and regulatory review. But when cryopreservation is standardized, documented, integrated with secure biostorage, and connected to qualified logistics and material movement, frozen starting material becomes a controlled input that can support predictable performance across regions.
As programs move toward later-stage development, trials cannot rely on each location managing cryopreservation its own way and then expect the outputs to behave as if they came from one unified process. They need workflows that create consistency at the point where fresh material is stabilized, then preserve that consistency through biostorage, transportation, and delivery into manufacturing.
Cryoport Systems’ integrated approach is built around that need, providing standardized IntegriCell cryopreservation that’s connected to the end-to-end supply chain infrastructure required to support global trial readiness.
